Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 pediatric ravulizumab study in generalized myasthenia gravis
jRCT2031230150Phase 3Active, not recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jul 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, open-label, single-arm trial of ravulizumab in myasthenia gravis (MG), sponsored by Alexion Pharmaceuticals. Primary endpoint: Pharmacokinetics and pharmacodynamics. Started Jul 2023; status: active, not recruiting.
02
Drugs
ravulizumab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on jRCT2031230150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230150.